5Klugman KP. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance [ J ]. Lancet Infect Dis, 2001, 1 (2) : 85-91.
6Pichichero ME, Bemstein H, Blatter MM, et al. Immtmogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococeal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine [J]. J Pediatr, 2007, 151(1): 4349.
7Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine [J]. N Engl J Med, 2003, 348(18) : 1737-1746.
8Lee LH, Lee C J, Frasch CE. Development and evaluation of pneumococcal conjugate vaccine: clinical trials and control tests [J]. Crit Rev Micmbiol, 2002, 28(1): 27-41.
9Ren B, Mccrory MA, Pass C, et al. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptormediated protection [ J ]. J Immunol, 2004, 173(12) : 7506-7512.
10Gor DO, DingX, Briles DE, et al. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae [ J ]. Infect Immun, 2005, 73 (3) : 1304-1312.
